AUR 103
Alternative Names: AUR 103 Calcium; AUR-103; AUR-103 calciumLatest Information Update: 02 Jul 2025
At a glance
- Originator Aurigene Discovery Technologies
- Developer Aurigene Oncology
- Class Antineoplastics; Small molecules
- Mechanism of Action CD47 antigen inhibitors; Phagocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Adenocarcinoma
- Phase I Acute myeloid leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 22 Mar 2025 Phase-I/II clinical trials in Adenocarcinoma (First-line therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in India (PO) (NCT07040059)
- 08 Jun 2023 Safety and pharmacokinetics data from a phase I BHARAT -1 trial in relapsed malignancies presented at 28th Congress of the European Hematology Association(EHA-2023)
- 16 Sep 2022 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy, Second-line or greater) in India (PO) (NCT05607199)